SU11248 demonstrated a dose-dependent increase in survival in a FLT3-ITD (MV4;11) bone marrow engraftment model.

(A) Kaplan-Meier plot of survival. At 3 weeks after intravenous MV4;11 cell implantation in cyclophosphamide-pretreated NOD-SCID mice, daily oral administration of SU11248 at 20, 10, or 5 mg/kg/d, or vehicle, was initiated and continued through the end of the experiment (10 mice per group). Mice exhibiting hind limb paralysis or signs of moribundity were humanely killed. (B) Bone marrow was collected for flow cytometric analysis of human CD45 expression as a marker for MV4;11 cells from naive controls and MV4;11-inoculated mice treated with vehicle or SU11248 (20 mg/kg/d). (C) Paraffin sections of bone marrow from vehicle-treated mice and SU11248-treated mice (20 mg/kg/d) were stained with H&E (left panels) or Ki67 (right panels). Representative results are shown.